TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03474380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iHI-FIVES
Description: Implementation of iHI-FIVES caregiver skills training
Study: NCT03807336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion-Focused Skills Training for Parents - Experiential
Description: The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emotion-Focused Skills Training for Parents - Experiential
Description: The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion-Focused Skills Training for Parents - Psychoeducational
Description: The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emotion-Focused Skills Training for Parents - Psychoeducational
Description: The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.
Study: NCT02828202

Intervention type: OTHER
Intervention: Biological
Description: DNA from peripheral blood mononuclear cells, RNA, plasma, serum sampled at inclusion, every 6 months and before each new systemic therapy.

Intervention type: OTHER
Intervention: Biological
Description: DNA from peripheral blood mononuclear cells, RNA, plasma, serum sampled at inclusion, every 6 months and before each new systemic therapy.

Intervention type: OTHER
Intervention: Tissular
Description: Primary melanoma (mostly paraffin embedded), metastatic sample (s)(paraffin embedded and frozen) from at least 1 site at inclusion and during evolution, particularly before treatment modification if clinically required.

Intervention type: OTHER
Intervention: Tissular
Description: Primary melanoma (mostly paraffin embedded), metastatic sample (s)(paraffin embedded and frozen) from at least 1 site at inclusion and during evolution, particularly before treatment modification if clinically required.
Study: NCT00063089

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S. aureus Immune Globulin Intravenous (Human) 5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S. aureus Immune Globulin Intravenous (Human) 5%
Study: NCT00644501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DiaPep277
Description: 1.0mg dose, injected subcutaneously at baseline and every 3 months thereafter (at 0, 3, 6, 9, 12, 15, 18, 21 months)for a total of 8 administrations.
Study: NCT00937014

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard infant formula
Description: Standard infant formula given during the first 9 months of life, as per standard requirement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test formula
Description: Test formula enriched in lactoferrin given during the first 9 months of life, as per standard requirement.
Study: NCT01056159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol dry powder inhaler
Description: Albuterol DPI (dry powder inhaler) delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol will be given on two treatment days (3 to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol in a DPI (dry Powder inhaler) and albuterol in an HFA MDI (hydrofluoroalkane metered dose inhaler), ProAir. One inhaler will contain active drug and one inhaler will contain placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler)
Description: Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler) delivers 90mcg of albuterol with each inhalation. Albuterol will be given on two treatment days (3to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol DPI (dry powder inhaler) and the comparator inhaler, albuterol HFA MDI (hydrofluoroalkane metered dose inhaler).One inhaler will contain active drug and one inhaler will contain placebo.
Study: NCT00082966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17-N-allylamino-17-demethoxygeldanamycin/bortezomib
Description: Given IV
Study: NCT02311062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric hamstring exercises
Description: Three exercises: 3 sets of 8 repetitions with 1 minute of rest between sets and 2 minutes of rest between exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unistable exercises
Description: Three exercises: 3 sets of 8 repetitions with 1 minute of rest between sets and 2 minutes of rest between exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Only soccer training
Study: NCT00808496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Biannual disease progression monitoring with peripheral magnetic resonance imaging of the 2nd to 5th metacarpophalangeal joints of the worst-effected or dominant hand at baseline. Scored using the Xie-modified rheumatoid arthritis magnetic resonance imaging score (RAMRIS).~MRI intervention group also undergoes radiography imaging. Only protocol determined smallest detectable changes on MRI reported.
Study: NCT02828202

Intervention type: OTHER
Intervention: Quality of life
Description: Specific questionnaires (FACT-M, EUROQUOL) at inclusion, every 3 months and before each new systemic therapy.

Intervention type: OTHER
Intervention: Quality of life
Description: Specific questionnaires (FACT-M, EUROQUOL) at inclusion, every 3 months and before each new systemic therapy.
Study: NCT01353976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Econazole Nitrate Foam 1%
Description: Econazole Nitrate Foam 1% applied once a day for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Vehicle foam applied once a day for 4 weeks
Study: NCT02872090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: inhalation
Study: NCT00808496

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radiography
Description: Biannual disease progression monitoring with radiography of both hands and wrists. Scored using the van der Heijde-modified Sharp score.~Radiography intervention group also undergoes MRI imaging. Only protocol determined smallest detectable changes on radiography reported.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Diagnostic imaging results (MRI or radiography) reported upon requisition. Standard of Care intervention group undergoes both MRI and radiography imaging. Upon requisition of either MRI or radiography, radiology reports are delivered as per institutional standard of care
Study: NCT01411657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-501 CNTF Implant
Description: Single implantation of CNTF-secreting NT-501 device into one eye
Study: NCT04511286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure
Description: Systematic confrontation with stimuli associated with symptom-related distress, to achieve therapeutic changes in cognitions or behavior
Study: NCT04349319

Intervention type: DEVICE
Group type: OTHER
Intervention: Digital preoperative planning
Description: Before the osteosynthesis of distal humerus fracture, we perform digital preoperative planning.
Study: NCT03142867

Intervention type: OTHER
Intervention: non-applicable
Description: non-applicable

Intervention type: OTHER
Intervention: non-applicable
Description: non-applicable

Intervention type: OTHER
Intervention: non-applicable
Description: non-applicable
Study: NCT00310609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine (Magnevist)
Description: Gadopentetate dimeglumine (Magnevist Injection), approximately 0.1mmol/kg body weight, single intravenous administration on the study day
Study: NCT02000752

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Study: NCT02593643

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: TAU includes any current treatment a patient is receiving from their primary care practitioner. In the major depressive disorder (MDD) group, TAU may include a newly initiated or longstanding antidepressant. In the bipolar depression (BD) group, TAU may include a mood stabilizer such as lithium or valproate that is a first or second line agent as per Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines (Yatham et al., 2013).
Study: NCT00295061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-1 MP
Description: alpha-1 proteinase inhibitor (human), 60 mg/kg body weight
Study: NCT02000752

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Sham point acupuncture
Study: NCT02964793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention group
Description: The intervention will include~1. clinician training sessions, designed to raise awareness of the importance of monitoring for FGR and standardizing SFH measurements~2. the use of SFH charts and EFW customised charts, built with the same software allowing all information to be recorded on an unique document~3. the use of the EFW values mentioned on US report, to plot EFW on the customised chart~4. and explicit recommendations about interpretation of longitudinal values of SFH and EFW measurements. If slopes through consecutive plots are not parallel to either of the predicted centile lines (90th, 50th, 10th) on the chart, and either of the centile lines are 'crossed', fetal biometry by ultrasound scan will be recommended.
Study: NCT02771626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: Glutaminase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: Glutaminase inhibitor
Study: NCT03360617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syringe IV Push over 2-3 minutes
Description: IV antibiotics will be administered by Syringe IV Push over 2-3 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Piggyback over 30 minutes
Description: IV antibiotics will be administered by IV Piggyback over 30 minutes.
Study: NCT02731066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard pro
Description: Volunteers will receive dietary protein at 1.0 ± 0.2 g/kg/d.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard pro
Description: Volunteers will receive dietary protein at 1.0 ± 0.2 g/kg/d.
Study: NCT00295061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alpha-1 proteinase inhibitor (human)
Description: Prolastin
Study: NCT02731066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High pro
Description: Volunteers will receive dietary protein at 2.0 ± 0.2 g/kg/d.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High pro
Description: Volunteers will receive dietary protein at 2.0 ± 0.2 g/kg/d.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: carbo bev
Description: During aerobic performance testing, volunteers will receive a beverage containing 80 g glucose + 65 g fructose consumed at a rate providing \~1.8 g carbohydrate/min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: carbo bev
Description: During aerobic performance testing, volunteers will receive a beverage containing 80 g glucose + 65 g fructose consumed at a rate providing \~1.8 g carbohydrate/min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo bev
Description: During aerobic performance testing, volunteers will receive a volume and flavor-matched, non-nutritive placebo beverage.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo bev
Description: During aerobic performance testing, volunteers will receive a volume and flavor-matched, non-nutritive placebo beverage.
Study: NCT00486304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADD
Description: The ADD has a composition of 65% carbohydrate, 20% fat, and 15% protein. The diet will be completely depleted of vitamins A, E and beta-carotene; it will have 10 mg of vitamin C (6.5% of RDA) added per person per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Jevity 1.5 (1.5 cal/mL) will be used for the placebo patients in this study. This will simulate the standard of care for patients not on the ADD. Jevity 1.5 is an isotonic, fiber-fortified, high-nitrogen liquid formula providing complete, balanced nutrition for patients requiring short- or long-term tube feeding, given once per day
Study: NCT02734706

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LRC™ capsule
Description: Twice per day (BID), 9 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Twice per day (BID), 9 weeks
Study: NCT02680015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEERS
Description: Social-behavioral intervention designed to help individuals with Autism Spectrum Disorder make and keep friends.
Study: NCT00413881

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WAVEFRONT- GUIDED LASIK ENHANCEMENT
Description: Laser treatment to correct residual refractive error left over from initial LASIK correction using wavefront guided LADARvision 4000 excimer laser system

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CONVENTIONAL LASIK ENHANCEMENT
Description: Laser treatment to correct residual refractive error left over from initial LASIK correction using LADARvision 4000 excimer laser system.
Study: NCT04301999

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy
Description: The PDT optical fiber was inserted through the dilation catheterand advanced toward the bile duct stenosis point under visualradiography. The dilation catheter was then withdrawn to leavethe PDT optical fiber directly across the stricture. Photoactivation was performed at 640 nm using a diode laser at a light dose of 180 J/cm2at power density of300 mW/cm2 and irradiation time of 600 s.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: an RFA electrode (Habib EndoHPB, EMcision, HitchinHerts, UK) was advanced along the guide wire into the bile duct and to the biliary stricture under X-ray fluoroscopic guidance. A 400 kHz RF generator (RITA 1500X, Angio Dynamics, USA) was connected for RFA at 7-10 W for 90 seconds.
Study: NCT01883063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical Treatment
Description: Patients will be treated for distal radius fractures surgically with a WRx™ Intramedullary Nail

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non surgical Treatment (Cast or splint)
Description: Patients will be treated for distal radius fractures non surgically with a cast or splint
Study: NCT01884038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treprostinil sodium
Description: A single dose strength of treprostinil sodium (1.0 mg/mL) and matching placebo will be provided in 20-mL multi-dose vials.~The study drug will be started after induction of anesthesia and increased incrementally to a target dose of 10 ng/kg/min during surgery and 48 hours post-operative

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02771626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: PD-1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: PD-1 inhibitor
Study: NCT02872090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: inhalation
Study: NCT04658784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-0 dioxanone, glycolide and trimethylene carbonate
Description: delayed absorbable, monofilament barbed suture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2-0 polydioxanone
Description: delayed absorbable, monofilament non-barbed suture
Study: NCT01423123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2 IV on days 1, 8, and 15 every 28 days until disease progression.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 4 mg/kg IV loading dose, then 2 mg/kg IV weekly until disease progression.
Study: NCT02378376

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arabinoxylan oligosaccharides

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary fiber enriched bran
Study: NCT02771626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: PD-1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: PD-1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: PD-1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: PD-1 inhibitor
Study: NCT05521633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and Pioglitazone
Description: Every participant in Group-A took tablet metformin 500 mg daily and every participant in Group-B took tablet pioglitazone 30 mg daily.
Study: NCT03014791

Intervention type: OTHER
Intervention: Brief lifestyle/medical history questionnaire
Description: Core Measurement

Intervention type: OTHER
Intervention: Brief lifestyle/medical history questionnaire
Description: Core Measurement

Intervention type: OTHER
Intervention: Brief lifestyle/medical history questionnaire
Description: Core Measurement

Intervention type: OTHER
Intervention: Anthropometric measures
Description: Core Measurement

Intervention type: OTHER
Intervention: Anthropometric measures
Description: Core Measurement

Intervention type: OTHER
Intervention: Anthropometric measures
Description: Core Measurement

Intervention type: OTHER
Intervention: Blood pressure and arterial stiffness
Description: Core Measurement

Intervention type: OTHER
Intervention: Blood pressure and arterial stiffness
Description: Core Measurement

Intervention type: OTHER
Intervention: Blood pressure and arterial stiffness
Description: Core Measurement

Intervention type: OTHER
Intervention: Cardiac output and lung function
Description: Core Measurement
Study: NCT02872090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Description: inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Description: inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Description: inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Description: inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: inhalation
Study: NCT01848470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG400549 640mg
Description: multiple oral doses of 640 mg CG400549 (n=6) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG400549 320 mg
Description: multiple oral doses of 320 mg CG400549 (n=6) QD for 5 days in the fed state
Study: NCT01650038

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment with faecal transplantation (donor faeces)
Description: faecal transplantation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: treatment with faecal transplantation (own faeces)
Description: faecal transplantation
Study: NCT03014791

Intervention type: OTHER
Intervention: Cardiac output and lung function
Description: Core Measurement

Intervention type: OTHER
Intervention: Cardiac output and lung function
Description: Core Measurement

Intervention type: OTHER
Intervention: Heart rate variability
Description: Core Measurement

Intervention type: OTHER
Intervention: Heart rate variability
Description: Core Measurement

Intervention type: OTHER
Intervention: Heart rate variability
Description: Core Measurement

Intervention type: OTHER
Intervention: Blood sample & spot urine sample
Description: Core Measurement

Intervention type: OTHER
Intervention: Blood sample & spot urine sample
Description: Core Measurement

Intervention type: OTHER
Intervention: Blood sample & spot urine sample
Description: Core Measurement
Study: NCT01423123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Dose level 1: 120 mg/day orally; Dose level 2: 160 mg/day orally; Dose level 3: 240 mg/day orally; Dose level 4: 200 mg/day orally.